JPMorgan analyst Lisa Gill raised the firm’s price target on Quest Diagnostics (DGX) to $190 from $180 and keeps a Neutral rating on the shares. The firm updated the company’s model post the Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics: Balancing Strong Q1 Performance with Moderate Future Growth Outlook
- Quest Diagnostics: Strong Growth Potential and Resilience Amidst Economic Uncertainty
- Quest Diagnostics price target raised to $190 from $182 at Truist
- Quest Diagnostics price target raised to $194 from $191 at Baird
- Quest Diagnostics: Resilience and Growth Potential Amidst Macroeconomic Challenges